The first patient has been dosed in another clinical trial evaluating our lead candidate EXL01 in the treatment of cancer!

Following the enrolment in the BIG trial announced last week in gastric cancer, this week we can also confirm that we have our first patient in the EXLIBRIS clinical trial in lung cancer! In the EXLIBRIS study EXL01 will be evaluated in second line, in combination with nivolumab, the same immune-checkpoint inhibitor already used in the BIG study. As 1 in 16 people can expect to be diagnosed with lung cancer in their lifetime, the importance of this trial cannot be understated.

EXLIBRIS study is one of three complementary clinical trials that are being conducted in parallel  to demonstrate the potential of EXL01 in immuno-oncology when combined with checkpoint inhibitors.

We extend our sincere thanks to the outstanding team leading the trial at the CHU de Lille, listed as one of the top five university hospitals in France for the quality of its research.